Streetwise Interviews

Jim Collins

Jim Collins Prescribes Five Micro-Cap Names to Build Portfolio Immunity
Source: JT Long of Streetwise Reports' Special Situations  (10/8/15)
In a volatile macroeconomic world, micro caps can offer some immunity as they move based on company news rather than front page headlines. But you have to pick your companies carefully. In this interview with Streetwise Reports' Special Situations, Jim Collins, founding partner of The Portfolio Guru, shares the names of a handful of companies he found in his travels to the LD Micro Conference and beyond. More >

Bernard Siegel

Advocacy and Technology Move Stem Cell Research Forward: Bernie Siegel of the Genetics Policy Institute
Source: Dan Levy of The Life Sciences Report  (10/7/15)
Regenerative medicine through stem cell technology is a source of hope for many suffering from ailments including Alzheimer's disease, diabetes, spinal cord injury and cancer. While new therapeutic options are continually in development, progress has, until recently, been hampered by political and medical ethics arguments. Because of patient advocacy, new technologies are now advancing, from development of an artificial pancreas to the hope of culturing intact human organs. In this interview with The Life Sciences Report, Bernie Siegel, founder and executive director of the Genetics Policy Institute, describes recent progress and developments in the regenerative medicine universe. More >

Hartaj Singh

BTIG's Hartaj Singh's Advice for Biotech Investors: 'Hold Your Powder' 'til Winter
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
While waiting for biotech stocks to correct, investors should be focused on performing due diligence, says Hartaj Singh of investment firm BTIG LLC. Growth in company valuations has outpaced sales for several years, but the coming weeks will see rapid fluctuations as the two begin to realign. In this interview, Singh shares his predictions for the rest of 2015 with The Life Sciences Report, and identifies several companies to hold for potentially big returns. More >


Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility. More >

Jason McCarthy

Slaying Oncology and Infectious Disease with Immunotherapy's Double-Edged Sword: Maxim Group's Jason McCarthy
Source: George S. Mack of The Life Sciences Report   (9/23/15)
Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant dual premise that enables one side to fund development of the other, and it seems to be working beautifully for companies and their shareholders. In this interview with The Life Sciences Report, McCarthy explains the principle and describes five companies proving up the model's profitability. More >

John McCamant Jay Silverman

Fallen Biotech Angels to Arise: John McCamant and Jay Silverman of the Medical Technology Stock Letter
Source: George S. Mack of The Life Sciences Report   (9/16/15)
It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter, and right now it's festival time as we approach the busy season of market-moving catalysts and milestones. From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report, McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years. More >

Joseph McAlinden

Alert: Veteran Investment Strategist Joe McAlinden Cautions Fed to Get Out of Business of Manipulating Stock Markets
Source: Gordon Holmes of Streetwise Reports  (9/16/15)
With the markets in whiplash mode, Joe McAlinden, founder of McAlinden Research Partners and former chief global strategist with Morgan Stanley Investment Management, believes volatility is going to stick around for a while. In fact, he just announced that we might see a correction double of what we've had so far. In this interview with Streetwise Reports, McAlinden bucks conventional wisdom and lays out his investing strategy for this period of market uncertainty. More >

Robert Erwin

The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. More >

Alan Leong

CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. Alan Leong, senior analyst with BioWatch, tells The Life Sciences Report about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies. He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies. More >

Ran Nussbaum

Buy Biotech When There's Blood on the Street: Pontifax's Ran Nussbaum
Source: George S. Mack of The Life Sciences Report   (9/2/15)
Ran Nussbaum, managing partner with The Pontifax Group, doesn't worry too much about overall market volatility. Biotechs, he feels, are somewhat immune to turmoil because their fundamentals are based in real life. He prefers to play on good science and unmet medical needs, and then sit tight until a stock is discovered. In this interview with The Life Sciences Report, Nussbaum describes a few takeover candidates primed for stellar growth, as well as promising names that are part of the movement toward personalized medicine. More >

Donald McCaffrey

Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey
Source: Gail Dutton of The Life Sciences Report  (8/26/15)
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events (MACE)—death, heart attacks, strokes and heart failure, particularly in diabetic patients—in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster. More >

David Nierengarten

Novel Technology Platforms with Dramatic Growth Potential: Wedbush's David Nierengarten
Source: George S. Mack of The Life Sciences Report  (8/26/15)
In the past five years, development of new therapies has aimed for true disease modification and actual cures. Many novel ideas are now in the clinic, and have opened up fresh opportunities for dramatic industry growth, especially in the gene and cellular therapy realm. In this interview with The Life Sciences Report, David Nierengarten of Wedbush Securities brings a handful of select names to investors' attention, including a couple of companies with technologies that could revolutionize medicine. More >

Bruce Campbell

Acquisitions Power Growth of Companies and Portfolios: StoneCastle's Bruce Campbell
Source: George S. Mack of The Life Sciences Report  (8/19/15)
Small-cap life science investors in the U.S. are focused on binary-event catalysts and major milestones that either propel stocks into the stratosphere or crash them to the ground. In Canada the focus is a bit different. Bruce Campbell of StoneCastle Investment Management has made a killing over the past year on rather unadventurous healthcare companies that have been acquiring smaller businesses and growing outward by fixing spokes to a hub. In this interview with The Life Sciences Report, Campbell describes five small-cap growth stories poised to ring up more acquisitions, more cash flow and more share price appreciation to portfolios. More >

Eden Rahim

Harness Biotech Volatility with an Options Strategy: Theta Strategy Capital's Eden Rahim
Source: George S. Mack of The Life Sciences Report  (8/12/15)
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names are called away by option buyers before the stock goes into the stratosphere? The answer is yes, and in this interview with The Life Sciences Report, Rahim describes his technique and leaves readers with six names that he fully expects to reap very large gains. More >

Gil Van Bokkelen

The Next Phase for MultiStem: Athersys' Gil Van Bokkelen
Source: George S. Mack of The Life Sciences Report   (8/12/15)
Regenerative medicine is surging toward the mainstream, and Athersys Inc. is riding the crest. Potential safety concerns surrounding cell therapies have been largely addressed, and now the efficacy of the company's MultiStem platform in several massive markets, including stroke, heart attack and acute pulmonary disease, are ready to be tested. As the company advances its portfolio of programs, Chairman and CEO Gil Van Bokkelen tells The Life Sciences Report about the promise that MultiStem holds for both patients and investors. More >

Colin Lee Novick

Regenerative Medicine in Japan: CJ PARTNERS' Colin Lee Novick
Source: Gail Dutton of The Life Sciences Report  (8/5/15)
Regenerative medicine is just beginning to be understood by governments and investors alike. Last autumn, new regulations took effect in Japan that promise to speed patient access to some of these new therapies. In this interview with The Life Sciences Report, Colin Lee Novick, managing partner with CJ PARTNERS, describes Japan's regenerative medicine frontier and lists investment-worthy companies that are pushing the boundaries. More >

Caroline Corner

Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices and Diagnostics Deliver Drugs and Profits
Source: George S. Mack of The Life Sciences Report  (7/29/15)
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis. Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors. In this interview with The Life Sciences Report, Corner brings important names to investors' attention. More >

John Hester

Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester of Bell Potter Securities
Source: George S. Mack of The Life Sciences Report  (7/22/15)
Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path. More >

Brian Marckx

Four Small-Cap Medtechs Primed for Outsize Returns: Zacks' Brian Marckx
Source: Staff of The Life Sciences Report  (7/15/15)
In the U.S., the medical device and diagnostics industry has been burdened with conflicting regulations that have delayed commercialization and complicated reimbursement. In this interview, Brian Marckx, senior medical device/diagnostics analyst with Zacks Investment Research, tells The Life Sciences Report how that situation is changing and identifies some innovative companies poised to make the most of the situation. More >

Joseph Patti

Biota Pharmaceuticals' Direct-Acting Antivirals Target the Root Cause of Viral Conditions
Source: Gail Dutton of The Life Sciences Report  (7/14/15)
Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. Dr. Joseph M. Patti, CEO of Biota Pharmaceuticals Inc., tells The Life Sciences Report about the novel antiviral therapies in his company's pipeline that address the cause of viral conditions, rather than merely the symptoms. More >

Jason Napodano

Zacks' Jason Napodano Is Not Focused on a Biotech Bubble
Source: George S. Mack of The Life Sciences Report  (7/8/15)
It's all about the fundamentals for Jason Napodano, CFA, of Zacks Investment Research. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and that there is still a huge thirst for early-stage devices, small molecules, biologics and cellular therapies. In this interview with The Life Sciences Report, Napodano details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios. More >

Marcel Wijma

Probe Biotech's Diverse Subsectors for Undervalued Companies: Van Leeuwenhoeck's Marcel Wijma
Source: Gail Dutton of The Life Sciences Report  (7/1/15)
The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today. This explosion of innovation also means an explosion of investment opportunity. In this interview with The Life Sciences Report, Marcel Wijma, chief research analyst at Van Leeuwenhoeck Institute, explores some smaller companies working on the industry's forefront. More >

Ron Najafi

A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals
Source: George S. Mack of The Life Sciences Report  (6/24/15)
What a difference just nine months can make. NovaBay Pharmaceuticals Inc. has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing the stock following a drug trial disappointment in mid-August 2014. In this interview with The Life Sciences Report, company founder, President and CEO Dr. Ramin "Ron" Najafi talks about the turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve. More >

George Zavoico

Opportunities in Cancer Immunotherapy Throttle Up: George Zavoico of JonesTrading
Source: George S. Mack of The Life Sciences Report  (6/24/15)
Biotech investors are abuzz over immune checkpoint inhibitors and T-cell therapies, but which ones do you pick? JonesTrading Institutional Services Senior Equity Analyst George Zavoico is moving rapidly to initiate coverage on some key names in this space, and is casting a wide net in hopes of catching winners. In this interview with The Life Sciences Report, Zavoico delineates some movers and shakers in the cancer immunotherapy field, and recommends investors keep their pencils sharp and eyes open as data emerge over the next year or two. More >

Joseph Pantginis

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners
Source: George S. Mack of The Life Sciences Report  (6/17/15)
The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation. In this interview with The Life Sciences Report, Pantginis discusses five names with development programs capable of generating dramatic growth. More >

Showing Results: 1 to 25 of 260 Next